KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Cash & Current Investments (2016 - 2025)

Sarepta Therapeutics (SRPT) has 15 years of Cash & Current Investments data on record, last reported at $237.9 million in Q3 2025.

  • For Q3 2025, Cash & Current Investments rose 20.25% year-over-year to $237.9 million; the TTM value through Dec 2025 reached $643.0 million, down 9.09%, while the annual FY2024 figure was $707.3 million, 57.8% down from the prior year.
  • Cash & Current Investments reached $237.9 million in Q3 2025 per SRPT's latest filing, down from $289.5 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $2.1 billion in Q4 2021 and bottomed at $197.9 million in Q3 2024.
  • Average Cash & Current Investments over 5 years is $1.4 billion, with a median of $1.7 billion recorded in 2021.
  • Peak YoY movement for Cash & Current Investments: rose 29.6% in 2022, then crashed 88.59% in 2024.
  • A 5-year view of Cash & Current Investments shows it stood at $2.1 billion in 2021, then dropped by 5.98% to $2.0 billion in 2022, then dropped by 15.74% to $1.7 billion in 2023, then tumbled by 57.8% to $707.3 million in 2024, then plummeted by 66.36% to $237.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Current Investments were $237.9 million in Q3 2025, $289.5 million in Q2 2025, and $522.8 million in Q1 2025.